DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Jones D, Boudes PF, Swain MG. , et al.
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Lancet Gastroenterol Hepatol 2017;
2 (10) 716-726
Access:
We do not assume any responsibility for the contents of the web pages of other providers.